Growth Peptides Compared: Sermorelin vs CJC-1295 vs Ipamorelin

Medical disclaimer: This article is for general education only — not medical advice, prescribing guidance, or instructions for self-administration. Prescription programs require evaluation by a licensed physician. Browse EllieMD programs → | Ask Aria →

Growth Hormone Secretagogues Explained

A secretagogue is any compound that stimulates the secretion of a hormone from its gland of origin. In peptide science, the most studied secretagogues target the pituitary gland — specifically, its production of growth hormone (GH).

There are two primary classes:

• GHRH analogs (Growth Hormone-Releasing Hormone) — like Sermorelin and CJC-1295 — mimic the body's natural GHRH signal, telling the pituitary to release GH in a pulsatile burst
• GHRPs (Growth Hormone-Releasing Peptides) — like Ipamorelin — bind ghrelin receptors on the pituitary, amplifying the GH release signal through a complementary pathway

Why does this category differ from direct HGH administration? Exogenous HGH shuts down natural pituitary production through negative feedback, produces unnaturally flat GH levels, and carries a broader side-effect profile (insulin resistance, joint pain, organ enlargement with chronic use). Secretagogues aim to restore the body's own pulsatile GH rhythm — higher peaks during sleep, lower troughs during the day — which more closely mimics youthful physiology.

Sermorelin: The Natural Pulse Mimic

Sermorelin is a GHRH analog comprising the first 29 amino acids of endogenous GHRH — the minimum sequence required for full receptor activity. Its short half-life (~10–20 minutes) means it produces a brief, sharp GH pulse that closely resembles natural secretion.

Research on Sermorelin has documented improvements in IGF-1 levels, body composition (lean mass increases with fat mass decreases over multi-month physician programs), and sleep quality — likely because the largest natural GH pulses occur during slow-wave sleep, and Sermorelin amplifies this nocturnal release.

Sermorelin is often chosen by patients who prioritize physiological GH pulsatility over sustained elevation. Its shorter half-life requires more frequent dosing (typically before bed on an empty stomach) but produces a cleaner hormonal profile than long-acting alternatives.

CJC-1295: With and Without DAC

CJC-1295 exists in two forms that patients must distinguish carefully:

Without DAC (also called Modified GRF 1-29 or Mod GRF 1-29): A GHRH analog with a half-life of approximately 30 minutes. It produces a sharp GH pulse similar to Sermorelin but with slightly greater amplitude. This is the form most commonly stacked with GHRPs like Ipamorelin.

With DAC (Drug Affinity Complex): DAC binds to serum albumin, extending the half-life to approximately 8 days. This produces sustained GH elevation rather than pulsatile release — a fundamentally different hormonal profile. Some patients prefer this for convenience (less frequent dosing); others avoid it because continuous GH elevation may not replicate natural physiology and can increase side-effect risk.

Research implications: the no-DAC form is generally preferred for physician-guided programs because its pulse aligns temporally with GHRP-induced amplification. The DAC form is sometimes used standalone for patients seeking sustained IGF-1 elevation without daily injections.

Ipamorelin: The Clean Secretagogue

Ipamorelin is a GHRP (Growth Hormone-Releasing Peptide) that binds ghrelin receptors on the pituitary. What distinguishes it from older GHRPs (GHRP-2, GHRP-6) is its selectivity — it stimulates GH release without significantly elevating cortisol or prolactin.

Elevated cortisol is catabolic (breaks down muscle) and counterproductive for recovery and body composition goals. Elevated prolactin can cause unwanted side effects including gynecomastia. Ipamorelin's clean profile makes it the GHRP of choice in most modern protocols.

Research findings for lean mass and recovery are consistent with GH secretagogue expectations: improved sleep quality within 2–3 weeks, gradual IGF-1 elevation over 8–12 weeks, and measurable changes in body composition when combined with adequate training and nutrition.

The CJC-1295 + Ipamorelin Stack

These two compounds are commonly researched together because their mechanisms are synergistic. GHRH analogs (CJC-1295 no DAC) and GHRPs (Ipamorelin) activate different receptors on the same pituitary somatotroph cells. When both signals arrive simultaneously, GH release is amplified beyond what either compound produces alone — a well-documented phenomenon in endocrinology research.

Typical protocol structures:

• CJC-1295 (no DAC): 100 mcg
• Ipamorelin: 100–200 mcg
• Timing: Before bed, fasted (insulin blunts GH release)
• Frequency: 5 days on, 2 days off (to prevent desensitization)
• Duration: 8–12 weeks, followed by 4-week break

Comparison Table

---

Explore EllieMD longevity programs | Ask Aria for a recommendation